Entresto’s Potential First-mover Advantage In Largely Untapped HFpEF Market Could Be Extremely Lucrative For Novartis

By Cyber Era Staff A positive recommendation from an FDA Advisory Committee has set Novartis’ Entresto (sacubitril/valsartan) on track to become the first drug to be approved for the treatment of heart failure with preserved ejection fraction (HFpEF). The potential label expansion could prove to be extremely lucrative for Novartis, providing the company with a first-mover advantage in this largely untapped market, says GlobalData. The committee voted 12 to one that data presented from the PARAGON-HF trial support usage of Entresto, an angiotensin receptor neprilysin inhibitor (ARNI), in reducing worsening...
1 2 3 33
Page 1 of 33